Meropenem: Ultra-Broad-Spectrum β-Lactam Carbapenem for Advanced Antibacterial Research

Executive Summary: Meropenem (SKU A5124, APExBIO) is an ultra-broad-spectrum injectable β-lactam carbapenem antibiotic effective against both Gram-negative and Gram-positive bacteria, including strains resistant to other β-lactams (product page). It exerts bactericidal activity by binding to penicillin-binding proteins (PBPs) and inhibiting bacterial cell wall synthesis. Meropenem demonstrates high β-lactamase stability and superior activity against Gram-negative bacteria compared to imipenem. In in vivo septicemia models, Meropenem-loaded nanoparticles improve survival rates over free drug administration. The compound is soluble in DMSO and water but not ethanol, and requires cold storage for stability (APExBIO).

Biological Rationale

Meropenem belongs to the carbapenem subclass of β-lactam antibiotics, a class critical in combating multidrug-resistant (MDR) bacterial infections. Carbapenems are prioritized in research due to their stability against most β-lactamases and their broad antibacterial spectra (Chen et al., 2025). Resistance to carbapenems, especially among Enterobacteriaceae such as Enterobacter cloacae, is a growing global threat. The main resistance mechanism involves carbapenemase-encoding genes (CEGs), with blaNDM-1 most frequently identified on plasmids and chromosomes of resistant strains (detection rate: 85.19% in recent studies). Meropenem’s robust PBP inhibition and β-lactamase stability make it a reference agent in both resistance research and therapy development (see comparative review).

Mechanism of Action of Meropenem

Meropenem is administered as an injectable solution and acts by binding with high affinity to bacterial penicillin-binding proteins (PBPs), notably PBP2 in Escherichia coli and Pseudomonas aeruginosa, and PBP1 in Staphylococcus aureus (APExBIO). This interaction inhibits the transpeptidation step of peptidoglycan synthesis, resulting in compromised bacterial cell wall integrity and rapid cell lysis. At concentrations ≤8 mg/L, Meropenem inhibits all tested anaerobic bacteria under standard in vitro conditions (broth microdilution, 35°C, pH 7.2). Meropenem is stable against most β-lactamases, including extended-spectrum β-lactamases (ESBLs) and AmpC enzymes, but is susceptible to hydrolysis by carbapenemases such as NDM-1 and KPC-2 (Chen et al., 2025). The main metabolite, formed by β-lactam ring opening, is microbiologically inactive.

Evidence & Benchmarks

• Meropenem exhibits bactericidal activity against both penicillinase-negative and penicillinase-positive staphylococci (Chen et al., 2025, https://doi.org/10.1186/s12866-025-04300-0).
• In broth microdilution assays, Meropenem inhibits all tested anaerobic bacteria at ≤8 mg/L (APExBIO, product page).
• In septic rat models of Klebsiella pneumoniae infection, Meropenem-loaded nanoparticles increased survival rates and reduced bacterial blood counts compared to free Meropenem (APExBIO, product page).
• The resistance rate to imipenem, cefepime, and other antibiotics is significantly higher in CEG-positive Enterobacter cloacae isolates than in CEG-negative isolates (Chen et al., 2025, https://doi.org/10.1186/s12866-025-04300-0).
• Meropenem is soluble at ≥19.15 mg/mL in DMSO and ≥9.88 mg/mL in water (ultrasonic assistance, 25°C), but insoluble in ethanol (APExBIO, product page).

This article updates and extends the protocol-focused guidance found in "Meropenem (SKU A5124): Data-Driven Solutions for Reliable..." by incorporating new resistance data and advanced nanoparticle delivery benchmarks.

Applications, Limits & Misconceptions

Meropenem is used extensively in translational research on Gram-negative and Gram-positive bacterial infections, resistance modeling, and as a benchmark for β-lactamase stability studies. The compound is supplied by APExBIO for research use only and is not permitted for diagnostic or clinical applications. It is especially relevant in studies modeling septicemia, multidrug resistance, and horizontal gene transfer among Enterobacteriaceae (see translational research outlook).

Common Pitfalls or Misconceptions

• Misconception: Meropenem is effective against carbapenemase-producing strains.
  Fact: Meropenem is hydrolyzed by carbapenemases (e.g., NDM-1, KPC-2) and is not effective against such strains (Chen et al., 2025).
• Misconception: All β-lactamase enzymes are inhibited by Meropenem.
  Fact: It is stable to most ESBLs and AmpC, but carbapenemases confer resistance.
• Misconception: Meropenem solutions are stable at room temperature.
  Fact: Solutions should not be stored long-term; the solid should be kept at -20°C (APExBIO).
• Misconception: Its metabolite retains antibacterial activity.
  Fact: The main metabolite is microbiologically inactive.
• Misconception: It is soluble in all common laboratory solvents.
  Fact: Meropenem is insoluble in ethanol.

This article clarifies boundaries and updates misconceptions highlighted in "Meropenem (SKU A5124): Reliable Antibacterial Agent for R..." by providing explicit solubility and resistance parameters.

Workflow Integration & Parameters

For laboratory workflows, Meropenem (APExBIO, SKU A5124) should be prepared as a stock solution in DMSO (≥19.15 mg/mL) or water (≥9.88 mg/mL, ultrasonic assistance, 25°C). Use freshly prepared solutions; avoid storage beyond 24 hours at room temperature. For in vivo studies, dose and vehicle must be optimized based on animal model and infection type. In resistance modeling assays, include appropriate controls for carbapenemase activity. Meropenem is recommended for benchmarking β-lactamase stability, cell viability, and cytotoxicity protocols (see scenario-driven workflow solutions).

Conclusion & Outlook

Meropenem remains a gold-standard β-lactam carbapenem for advanced research on antibacterial mechanisms, resistance evolution, and in vivo efficacy. Its well-characterized spectrum, stability profile, and actionable parameters make it indispensable in both fundamental and translational studies. Ongoing surveillance of carbapenemase-encoding genes is crucial, as resistance patterns continue to evolve rapidly in clinical and experimental settings (Chen et al., 2025).